Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 3 Open-Label Switch Over Study to Assess Safety, Efficacy & PK of Pegunigalsidase Alfa (PRX-102) 2mg/kg IV Every 4 Weeks for 52 Weeks in Fabry Disease Patients Currently Treated With Enzyme Replacement Therapy Fabrazyme® or Replagal™

NCT03180840 is registered in ClinicalTrials.gov with Protalix as lead sponsor.

NCT NCT03180840
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03180840 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 3 Open-Label Switch Over Study to Assess Safety, Efficacy & PK of Pegunigalsidase Alfa (PRX-102) 2mg/kg IV Every 4 Weeks for 52 Weeks in Fabry Disease Patients Currently Treated With Enzyme Replacement Therapy Fabrazyme® or Replagal™
Lead sponsor
Protalix
Phase
Phase 3
Overall status
Completed
Start date
July 10, 2017
Completion date
August 1, 2020
Enrollment
30 (actual)
Sites
14

Conditions

As the registry lists them; a condition with its own page is linked.

fabry disease